[go: up one dir, main page]

WO2001060848A3 - Conjugues cibles sur des recepteurs cibles - Google Patents

Conjugues cibles sur des recepteurs cibles Download PDF

Info

Publication number
WO2001060848A3
WO2001060848A3 PCT/US2001/005225 US0105225W WO0160848A3 WO 2001060848 A3 WO2001060848 A3 WO 2001060848A3 US 0105225 W US0105225 W US 0105225W WO 0160848 A3 WO0160848 A3 WO 0160848A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor
cell
chemical agent
target
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/005225
Other languages
English (en)
Other versions
WO2001060848A2 (fr
Inventor
Ramesh K Prakash
Christopher G Anderson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Finance LLC
Original Assignee
Watson Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Watson Pharmaceuticals Inc filed Critical Watson Pharmaceuticals Inc
Priority to AU2001241549A priority Critical patent/AU2001241549A1/en
Priority to EP01912804A priority patent/EP1255568A2/fr
Priority to CA002398395A priority patent/CA2398395A1/fr
Publication of WO2001060848A2 publication Critical patent/WO2001060848A2/fr
Publication of WO2001060848A3 publication Critical patent/WO2001060848A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Un conjugué d'apport intracellulaire d'un agent chimique dans un récepteur cible tel qu'une cellule porteuse de récepteur d'interleukine-2, par exemple un lymphocyte T activé et une cellule cancéreuse, comprend un agent chimique, au moins une copie du ligand fixant le récepteur cible et induisant une endocytose, couplé à un polymère hydrosoluble. Le ligand se fixe à un récepteur cible tel qu'un récepteur d'Il-2 sur la cellule portant le récepteur cible et il met en lumière une endocytose du conjugué. Le conjugué comprend aussi facultativement un espaceur biodégradable destiné à coupler l'agent chimique et le ligand au polymère. Les agents chimiques peuvent comprendre des cytotoxines, des acides nucléiques transformants, des régulateurs de gènes, des étiquettes, des antigènes, des médicaments et analogues. Le polymère hydrosoluble préféré est un oxyde de polyalkylène, tel qu'un polyéthylène glycol et un oxyde de polyéthylène, ainsi que leurs dérivés activés. L'invention concerne également des procédés d'utilisation de ces compositions pour administrer un agent chimique in vivo ou in vitro. L'invention concerne aussi des méthodes de détection d'une maladie, telle que le cancer, la leucémie lymphoïde à cellules T, la leucémie aiguë lymphoblastique à cellules T, le lymphome malin à cellules T périphériques, la maladie de Hodgkin, ainsi que l'hématosarcome non Hodgkinien, associée à des niveaux élevés de récepteur cible soluble et/ou de récepteur d'IL-2.
PCT/US2001/005225 2000-02-18 2001-02-15 Conjugues cibles sur des recepteurs cibles Ceased WO2001060848A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2001241549A AU2001241549A1 (en) 2000-02-18 2001-02-15 Conjugates targeted to target receptors
EP01912804A EP1255568A2 (fr) 2000-02-18 2001-02-15 Conjugues cibles sur des recepteurs cibles
CA002398395A CA2398395A1 (fr) 2000-02-18 2001-02-15 Conjugues cibles sur des recepteurs cibles

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50714000A 2000-02-18 2000-02-18
US09/507,140 2000-02-18

Publications (2)

Publication Number Publication Date
WO2001060848A2 WO2001060848A2 (fr) 2001-08-23
WO2001060848A3 true WO2001060848A3 (fr) 2002-04-25

Family

ID=24017414

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/005225 Ceased WO2001060848A2 (fr) 2000-02-18 2001-02-15 Conjugues cibles sur des recepteurs cibles

Country Status (4)

Country Link
EP (1) EP1255568A2 (fr)
AU (1) AU2001241549A1 (fr)
CA (1) CA2398395A1 (fr)
WO (1) WO2001060848A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE50312971D1 (de) * 2002-04-29 2010-09-23 Biotesys Gmbh Polymerisierte peptid-modifizierte lipide als biologische transportsysteme für mikronutrients

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997038011A1 (fr) * 1996-04-03 1997-10-16 Pepresearch A/S Porteur peptidique non-dendritique d'ossature
CZ283008B6 (cs) * 1993-07-20 1997-12-17 Ústav Makromolekulární Chemie Av Čr Polymerní konjugát cyklosporinu A, způsob jeho přípravy a použití v in vitro diagnostických testech, způsob stanovení volného cyklosporinu A a jeho metabolitů in vitro v lidských tělních tekutinách
WO1999007324A2 (fr) * 1997-08-05 1999-02-18 Watson Pharmaceuticals, Inc. Conjugues cibles apportes au recepteur de l'interleukine-2
WO2000007543A2 (fr) * 1998-08-04 2000-02-17 Watson Laboratories, Inc.-Utah Conjugues cibles apportes aux recepteurs cibles et/ou aux recepteurs de l'interleukine 2

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ283008B6 (cs) * 1993-07-20 1997-12-17 Ústav Makromolekulární Chemie Av Čr Polymerní konjugát cyklosporinu A, způsob jeho přípravy a použití v in vitro diagnostických testech, způsob stanovení volného cyklosporinu A a jeho metabolitů in vitro v lidských tělních tekutinách
WO1997038011A1 (fr) * 1996-04-03 1997-10-16 Pepresearch A/S Porteur peptidique non-dendritique d'ossature
WO1999007324A2 (fr) * 1997-08-05 1999-02-18 Watson Pharmaceuticals, Inc. Conjugues cibles apportes au recepteur de l'interleukine-2
WO2000007543A2 (fr) * 1998-08-04 2000-02-17 Watson Laboratories, Inc.-Utah Conjugues cibles apportes aux recepteurs cibles et/ou aux recepteurs de l'interleukine 2

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; ULBRICH, KAREL ET AL: "Polymeric conjugate of cyclosporin A, process of its preparation and use for in vitro diagnostic tests, method of determining free cyclosporin A and its metabolites in vitro in human body fluids", XP002187324, retrieved from STN Database accession no. 130:335013 CA *

Also Published As

Publication number Publication date
WO2001060848A2 (fr) 2001-08-23
AU2001241549A1 (en) 2001-08-27
CA2398395A1 (fr) 2001-08-23
EP1255568A2 (fr) 2002-11-13

Similar Documents

Publication Publication Date Title
WO2000007543A3 (fr) Conjugues cibles apportes aux recepteurs cibles et/ou aux recepteurs de l'interleukine 2
Kolakowski et al. The methylene alkoxy carbamate self‐immolative unit: utilization for the targeted delivery of alcohol‐containing payloads with antibody–drug conjugates
EP2596803A3 (fr) Procédé de ciblage de populations de cellules spécifiques au moyen de conjugués de maytansinoïdes avec des agents se liant aux cellules, liés par une liaison non clivable, lesdits conjugués et procédés de fabrication desdits conjugués
Pechar et al. Poly (ethylene glycol) multiblock copolymer as a carrier of anti-cancer drug doxorubicin
Hamilton Antibody-drug conjugates for cancer therapy: The technological and regulatory challenges of developing drug-biologic hybrids
EP0974344A3 (fr) Composition et forme du dosage pharmaceutique faite en polysaccharides permettant une libération controllée au côlon
Nori et al. Intracellular targeting of polymer-bound drugs for cancer chemotherapy
US9056129B2 (en) Precision-guided nanoparticle systems for drug delivery
WO2002100336A3 (fr) Proteines membranaires endotheliales a specificite tissulaire
WO2005053749A3 (fr) Liaison liberable et compositions la contenant
Cho et al. Folate receptor‐mediated gene delivery using folate‐poly (ethylene glycol)‐poly (L‐lysine) conjugate
US20130203675A1 (en) Asymmetric biofunctional silyl monomers and particles thereof as prodrugs and delivery vehicles for pharmaceutical, chemical and biological agents
WO2007047922A3 (fr) Conjugues polymeres-medicaments
TR199902731T2 (xx) Kimyasal bile�ikler.
WO1997032572A3 (fr) Materiaux et procedes permettant d'accroitre la penetration intracellulaire
EP2348024A3 (fr) Procédé de préparation de conjugués cytotoxiques de maytansinoïdes et agents de liaison de cellules
EP2338513A3 (fr) Conjugués polymères liberables fondés sur des lieurs biodegradables aliphatiques
Olson et al. Antibody-drug conjugates targeting prostate-specific membrane antigen
Etrych et al. HPMA copolymer conjugates with reduced anti-CD20 antibody for cell-specific drug targeting. I. Synthesis and in vitro evaluation of binding efficacy and cytostatic activity
AU2002225878A1 (en) Receptor antagonist-lipid conjugates and delivery vehicles containing same
WO2004062588A3 (fr) Systeme de liberation de medicament polymerique soluble dans l'eau ciblant les os
AU2001276831A1 (en) Delivery vehicle composition and methods for delivering antigens and other drugs
WO2001004334A3 (fr) Infection par adenovirus chimerique de cellules qui sont negatives pour le recepteur d'adenovirus de coxsacki (car) de serotypes 5 d'adenovirus
WO2001060848A3 (fr) Conjugues cibles sur des recepteurs cibles
HK1047884A1 (zh) 生物活性材料

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2398395

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001241549

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001912804

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001912804

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2001912804

Country of ref document: EP